



# Iowa Department of Human Services

Terry E. Branstad  
Governor

Kim Reynolds  
Lt. Governor

Charles M. Palmer  
Director

## Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

June 7, 2017

**Location:** Learning Resource Center  
3550 Mills Civic Parkway  
West Des Moines, Iowa, 50265  
Fairmeadows Room

**Time:** 9:30 a.m. – 1:30 p.m.

### Final Agenda

1. Welcome & Introductions
  - a) Commission Members and Staff
2. Commission Business
  - a) Approval of the Minutes
  - b) DHS Recommendation Letter – April 2017
  - c) P & T Committee Recommendation Letter
  - d) Advocates for Opioid Recovery Letter
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
  - a) Amerigroup
  - b) United Healthcare Community Plan
  - c) AmeriHealth Caritas Iowa
6. Public Comment\* (See Conflict of Interest Disclosure Form)
7. Retrospective Claims Analysis
  - a) Concomitant Use of Benzodiazepines and Opioids
8. ProDUR Edits
  - a) Injectable Anticoagulant Quantity Limits – Second Review
9. Prior Authorization
  - a) Prior Authorization Process
    - i. American Medical Association Prior Authorization and Utilization Management Reform Principles <https://www.ama-assn.org/sites/default/files/media->

[browser/principles-with-signatory-page-for-slsc.pdf](http://www.iadur.org/browser/principles-with-signatory-page-for-slsc.pdf)

ii. Iowa House File 233 – Step Therapy Protocols for Prescription Drugs

- b) Deflazacort (Emflaza) – Initial Review
- c) Hepatitis C Treatments – Initial Review
- d) Omalizumab (Xolair) – Initial Review
- e) Crisaborole (Eucrisa) – Initial Review
- f) Eluxadoline (Viberzi) – Initial Review
- g) New to Market Drugs – Initial Review
- h) High Dose Opioid ( $\geq 90$  MME/day) – Second Review (Updated)
- i) GLP-1 Agonist/Basal Insulin Combinations – Second Review
- j) Calcifediol (Rayaldee) – Second Review
- k) Lesinurad (Zurampic) – Second Review
- l) Sapropterin (Kuvan) – Second Review

10. Miscellaneous

- a) DUR Digest Vol. 29, No. 3 – Second Review
- b) MedWatch

11. Adjournment

\*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

[www.iadur.org](http://www.iadur.org)

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at [info@iadur.org](mailto:info@iadur.org) or (515) 974-3131

**\*\*\*Next Meeting August 2, 2017\*\*\***  
**Learning Resource Center**  
**3550 Mills Civic Parkway, West Des Moines, IA**